MCSGP shows promise in addressing one of AAV manufacturing's greatest conundrums — separating full capsids from the empty and partially-filled ones.
- Five APAC Markets, Five Regulatory Models: What Developers Should Know
- Applying The Multiproduct Manufacturing Model To Autologous Cell Therapy
- You Can't CAPA What You Can't Locate
- Safety, Durability, And Trial Design: Testing One-Time Dose To Slow Huntington's
- Computational Model Predicts Huntington's Drug Performance
- Comparing Advanced Modality Needs, Part 1: Manufacturing
- What Will It Take To Turn CGT Innovation Into Market Success?
- Why CMC Must Shape Critical Decisions Early In Development
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
21% Of CGT Clinical Holds Stem From CMC Issues. What Does This Tell Us?
Cell and gene therapy (CGT) trials account for nearly 40% of all clinical holds reported by the NIH, with over 21% caused by CMC issues, often delaying approvals by over 6 months.
-
Essential Strategies For Effective Viral Clearance Studies In Biologics Manufacturing
Strengthen your viral safety strategy by applying science- and risk-based approaches to viral clearance planning, ensuring robust data, regulatory compliance, and patient protection.
-
Powering More Efficient Clinical Development With AI And ML
Explore how AI and ML are revolutionizing clinical trials by automating data processes to accelerate research and transform data into actionable outcomes for patient care.
-
Unlocking Durable Allogeneic Cell Therapy
Advances in genome engineering and immune evasion are enabling scalable, durable allogeneic cell therapies, overcoming rejection challenges and expanding potential treatments across diverse diseases.
-
Leveraging Single-Use Solutions To Solve Working Cell Bank Challenges
Discover how custom manifolds enhance allogeneic therapy development from formulation to commercialization by improving process control, scalability, and efficiency.
-
Rescuing A Global Full-Service Phase III Trial For A Late-Stage Oncology Biotech
This case underscores the expertise employed in a comprehensive strategy and set of services that were used to salvage a Phase III clinical trial for ovarian cancer and ensure its timely completion.
-
Manufacturing of "MSC 2.0" Using Functionally Closed Systems
Transitioning to closed systems enables the 100-fold expansion of engineered cells. Achieve high yields and maintain anti-cancer potency while reducing contamination risks and labor.
-
From Variability To Validation – GMP Bioassay Success Through Partnership
Turn your inconsistent bioassays into GMP-validated, high-reliability platforms — just like we helped a biopharma partner cut failure rates from ~25% to <1%.
-
The True ROI Of Decentralized Clinical Trials
Gain a greater understanding of how the right DCT solution, or combination of solutions, coupled with clear metrics and expert guidance on execution, can demonstrate tangible, quantitative ROI in clinical trials.
-
Nectin 4 Biomarker Testing For Oncology Clinical Programs
No validated test existed for a key tumor biomarker. See how a tissue-staining assay was built, validated, and scaled to select the right patients for a cancer trial.
NEWSLETTER ARCHIVE
- 11.20.26 -- Want More Sustainable Biopharma Packaging? Try These Levers
- 11.19.26 -- OPCU: Strengthening Large Molecule Programs From Manufacturing To Fill-Finish
- 11.19.26 -- Exploring Earlier Gene Editing For Children With Dr. Haydar Frangoul, Part 2
- 11.18.26 -- OPCU: Strengthening Cell And Gene Therapy Programs With Robust Analytics
- 11.18.26 -- What Will It Take To Turn CGT Innovation Into Market Success?
- What Will It Take To Turn CGT Innovation Into Market Success?
- Exploring Earlier Gene Editing For Children With Dr. Haydar Frangoul, Part 2
- Exploring Earlier Gene Editing For Children With Dr. Haydar Frangoul, Part 1
- Earlier Decisions, Better Processes Required For Automating Autologous CAR T Manufacturing
- Why In Vivo Innovation, Regulatory Convergence Will Help Shape CGT's Next Chapter
EDITORIAL COLLECTIONS KNOWLEDGE CENTER
Our Editorial Collections examine today’s biggest scientific, operational, and patient-centered drug delivery issues. These collections help companies navigate complex development decisions with in-depth analysis, real-world examples, and guidance from industry experts
More Editorial Collections

